Amneal Pharmaceuticals (AMRX) Total Debt (2017 - 2025)
Historic Total Debt for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $2.6 billion.
- Amneal Pharmaceuticals' Total Debt rose 749.29% to $2.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 billion, marking a year-over-year increase of 749.29%. This contributed to the annual value of $2.4 billion for FY2024, which is 697.86% down from last year.
- As of Q3 2025, Amneal Pharmaceuticals' Total Debt stood at $2.6 billion, which was up 749.29% from $2.4 billion recorded in Q2 2025.
- Over the past 5 years, Amneal Pharmaceuticals' Total Debt peaked at $2.8 billion during Q1 2021, and registered a low of $2.4 billion during Q4 2024.
- Over the past 5 years, Amneal Pharmaceuticals' median Total Debt value was $2.7 billion (recorded in 2022), while the average stood at $2.6 billion.
- Per our database at Business Quant, Amneal Pharmaceuticals' Total Debt crashed by 1022.13% in 2021 and then surged by 749.29% in 2025.
- Quarter analysis of 5 years shows Amneal Pharmaceuticals' Total Debt stood at $2.7 billion in 2021, then decreased by 2.78% to $2.7 billion in 2022, then fell by 3.28% to $2.6 billion in 2023, then fell by 6.98% to $2.4 billion in 2024, then grew by 7.87% to $2.6 billion in 2025.
- Its Total Debt stands at $2.6 billion for Q3 2025, versus $2.4 billion for Q2 2025 and $2.4 billion for Q1 2025.